Leflunomide-induced Toxic Epidermal Necrolysis in a Patient with Rheumatoid Arthritis.
10.4078/jrd.2014.21.6.326
- Author:
Ji Hye JE
1
;
Hyun Jung LEE
;
Young Ju NA
;
Ji Hye SEO
;
Young Ho SEO
;
Jae Hoon KIM
;
Sung Jae CHOI
;
Young Ho LEE
;
Jong Dae JI
;
Gwan Gyu SONG
Author Information
1. Division of Rheumatology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Korea. csjmd@hotmail.com
- Publication Type:Case Report
- Keywords:
Leflunomide;
Toxic epidermal necrolysis;
Rheumatoid arthritis
- MeSH:
Arthritis, Rheumatoid*;
Cholestyramine Resin;
Humans;
Hyperpigmentation;
Immunoglobulins;
Korea;
Methylprednisolone;
Skin;
Stevens-Johnson Syndrome*
- From:Journal of Rheumatic Diseases
2014;21(6):326-330
- CountryRepublic of Korea
- Language:English
-
Abstract:
Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998 and has been available in Korea since 2003. Allergic cutaneous reactions (rash, purpura) are common (<10%) side effects of leflunomide, but severe cases such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) are rarely reported. There has not been a report of SJS or TEN induced by leflunomide in Korea. Here we report a case of leflunomide-induced TEN in a patient with rheumatoid arthritis. Leflunomide was discontinued, and the TEN was treated with methylprednisolone, cholestyramine and immunoglobulin. The skin lesion eventually resolved over four weeks with residual post-inflammatory hyperpigmentation.
